Have a personal or library account? Click to login
Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis Cover

Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis

Open Access
|Mar 2024

Abstract

Lung cancer (LC) is the leading cause of cancer deaths worldwide. Surgery, chemoradiotherapy, targeted therapy, and immunotherapy are considered dominant treatment strategies for LC in the clinic. However, drug resistance and meta-stasis are two major challenges in cancer therapies. Medicarpin (MED) is an isoflavone compound isolated from alfalfa, which is usually used in traditional medicine. This study was de sig ned to evaluate the anti-LC effect and reveal the underlying mechanisms of MED in vivo and in vitro. We found that MED could significantly inhibit proliferation, induce apoptosis, and cell cycle arrest of A549 and H157 cell lines. Basically, MED induced cell apoptosis of LC cells by upregu lating the expression of pro-apoptotic proteins BAX and Bak1, leading to the cleavage of caspase-3 (Casp3). Moreover, MED inhibited the proliferation of LC cells via downregulating the expression of proliferative protein Bid. Overall, MED inhibited LC cell growth in vitro and in vivo via suppressing cell proliferation and inducing cell apoptosis, suggesting the therapeutic potential of MED in treating LC.

DOI: https://doi.org/10.2478/acph-2024-0006 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 149 - 164
Accepted on: Feb 13, 2024
Published on: Mar 30, 2024
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2024 Zongyi Shen, Liqi Yin, Manxia Chang, Haifeng Wang, Mingxuan Hao, Youfeng Liang, Rui Guo, Ying Bi, Jiansong Wang, Changyuan Yu, Jinmei Li, Qiongli Zhai, Runfen Cheng, Jinku Zhang, Jirui Sun, Zhao Yang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.